Adaptiv Select ETF (ADPV)
Live price chart, market sentiment, and community perspectives for Adaptiv Select ETF (AMEX: ADPV).
Live price chart, market sentiment, and community perspectives for Adaptiv Select ETF (AMEX: ADPV).
On our desk, we are viewing ADPV through a purely tactical lens. The strategy's automated pivot between high-beta momentum stocks and Treasury bills makes it an intriguing vehicle for market timing, but the high fee structure and historical propensity for fast drawdowns mean we cannot treat it as a core buy-and-hold allocation. It requires active monitoring of its tech and energy sleeves.
From a risk management standpoint, the Morningstar risk score of 95 places ADPV firmly in the 'Very Aggressive' bucket. Even though its 3-year Sharpe ratio of 0.88 outperforms the category median of 0.50, its maximum drawdown of -13.64% and thin secondary market volume expose holders to significant spread risk during cyclical pivots.
From a fundamental valuation perspective, ADPV offers an attractive forward P/E of 15.6. However, technical analysis shows the price stalling right on its 200-day moving average of $42.17. We are advising clients to closely monitor the $43.57 price level and upcoming Q3 earnings to determine if a sustainable uptrend can clear these overhead hurdles.
Looking at the quant architecture, the fund's proprietary model targets a non-diversified basket of roughly 27 holdings with nearly half the assets concentrated in the top ten names. When analyzing its capture ratios, we note a beta of 1.07 and a standard deviation of 19.73, which underscores why this instrument is built strictly for risk-tolerant allocators rather than conservative portfolios.
Social sentiment tracking across StockTwits and Twitter reveals a crowd psychology that is deeply split. While retail momentum chasers praise its aggressive upside recovery phases, institutional reports show steady Q2 participation with 19 funds holding $162M, though new positions and exits netted out flat at 3 additions and 3 closures.
Explore plasma cleansing, somatic organ swaps, and BCI.